Gene knock-out of the omega-1 ribonuclease of Schistosoma mansoni eggs resulted in immunologically impaired phenotype, showcasing the novel application of CRISPR/Cas9 genome editing and utility for functional genomics in schistosomes.

RNA degradation is completed through specific intermediates, such as diribonucleotides, which must be removed from the cells by a specific enzyme.

AGO protein-interacting exoribonucleases clear RNA induced silencing complex (RISC)-resulting 5' cleavage products in time to recycle RISC and miRNAs.

Endogenous double-stranded RNA is generated in human cells and leads to RNase L activation and consequent cell death unless neutralized by adenosine deaminase acting on RNA1 (ADAR1).

The novel cryo-electron microscopy structure of a bacterial protein-only RNase P illustrates how a small protein oligomerizes into a dodecameric assembly to catalyze the 5’-end maturation of tRNAs.

The dynamic interplay between type III CRISPR enzymes governs cyclic nucleotide levels and infection outcomes in virus-host conflict.

Dinucleases, specialized enzymes that catalyze the final step in RNA degradation, have evolved independently and repeatedly to fulfill essential roles in cell growth.

Small regulatory RNAs are able to modulate mRNA degradation rates by controlling access to the 5' end of mRNAs in bacteria.

Generation of the anti-viral second messenger cyclic oligoadenylate by type III CRISPR systems is tightly controlled in response to viral RNA load and sequence.